Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants

Mise à jour : Il y a 4 ans
Référence : NCT00138060

Femme et Homme

  • | Pays :
  • France
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

This study intends to optimize a fluorouracil/irinotecan chemotherapy regimen by the identification of individual thymidylate synthase (TS) and UDP-glucuronosyltransferase 1 (UGT1A1) polymorphisms before the first administration. The results of this identification determine the chemotherapy type: high-dose irinotecan or not.


Critère d'inclusion

  • Metastatic colorectal cancer

Liens